Select Page

EudraLex – amount 2 – Pharmaceutical legislation on notice to applicants and regulatory recommendations

Amount 2 associated with the magazines “the guidelines regulating medicinal items in europe” contains a listing of regulatory tips pertaining to procedural and regulatory needs such as for instance renewal procedures, dossier requirements for Type IA/IB variation notifications, summary of item characteristics (SmPC), package information and category for the supply, readability of this label and package leaflet demands.

The Notice to Applicants below was served by the Commission that is european consultation because of the competent authorities regarding the Member States plus the European Medicines Agency (EMA). This Notice doesn’t have appropriate force and doesn’t always express the ultimate views of this Commission. In case there is doubt, therefore, guide ought to be built to the correct Union Directives and Regulations.

The Notice to Applicants was posted in 1986 and it is regularly updated.

Amount 2A – Procedures for advertising authorisation

  • Chapter 1 – Marketing Authorisation (updated variation – 2019 july)
  • Chapter 2 – Mutual Recognition (updated variation – February 2007)
  • Chapter 3 – Union Referral treatments (updated variation – 2018 november)
  • Chapter 4 – Centralised Procedure (deleted – July 2015). The European Medicines Agency is in charge of the clinical assessment of applications for European Union (EU) marketing authorisations for individual and veterinary medications into the procedure that is centralised. No dedicated chapter on the centralised procedure has been included in the NTA as the Agency provides relevant information and guidance for companies and individuals involved in developing and marketing medicines for human use in the Union. To be noted that this guidance just isn’t a NTA document any longer. Regular change with this guidance will likely to be available entirely on the website that is relevant.
  • Chapter 5 – instructions of 16 May 2013 from the information on the different kinds of variants, in the procedure regarding the procedures laid straight straight down in Chapters II, IIa, III and IV of Commission Regulation (EC) No 1234/2008 of 24 November 2008 regarding the study of variants to your regards to advertising authorisations for medicinal services and products for human being usage and veterinary medicinal services and products and regarding the paperwork to be submitted pursuant to those procedures – C (2013) 2804 (OJ C 223, 2.8.2013, p. 1–79).
    • PDF variation (might 2013)
    • Word version (May 2013)
  • Please additionally note the notice of 12/10/2009:

    “Droit de respect”: crucial notice to stakeholders – follow-up to the notice of 29/07/09

    After an understanding because of the accountable Committee within the European Parliament as well as in conformity utilizing the interinstitutional agreement of 3 June 2008, the time for the “droit de respect” for the Commission choices taken within the “Decision making procedure” is reduced for a permanent foundation to seven days. This is applicable additionally when you look at the recess durations of European Parliament.

    The period that is shortened of “droit de respect” does, but, maybe maybe not use within the following instances:

    • The draft Commission choice is certainly not according to the clinical viewpoint associated with EMA;
    • Member States, throughout the vote, demand that the draft choice is talked about in a plenary conference associated with Standing Committee; or
    • The viewpoint for the Standing Committee is unfavourable.

    The “Notice to candidates”, Chapter VI, is likely to be updated to the impact.

    This arrangement is applicable with instant impact, in other words.:

    • Procedures when you look at the Comitology stage that have been into the “droit de regard” phase for over 1 week will be moved in to the use stage (15 calendar times);
    • Procedures within the Comitology stage that are nevertheless within the voting stage of Member States is going to be susceptible to a period that is shortened of de regard” of seven days.

    Used, the excess seven days for the “droit de regard” following vote by Member States may be utilized to get ready the ultimate decision for use when the 1 week have actually expired. Therefore, in training, the timelines will never be much affected because of the “droit de respect”.

    Organizations are kindly required to keep from ringing up the Commission staff to “urge” a quicker processing of this draft choice of “their” products.

  • Chapter 7 – General Information details about peoples medicinal items authorised centrally and nationwide (Mutual Recognition Procedure/DeCentralised Procedure) found in this Chapter is utilized in EMA and CMDh sites correspondingly. A summary of papers changing the earlier chapters of Chapter 7 with corresponding web site references can be obtained during the after target.
    • For CMDh, see document en titled: “Transfer of information found in Notice to candidates, Volume 2A, Chapter 7”
    • For EMA:
      • Pre-authorisation
      • Post-authorisation

Consequently any mention of chapter 7 ought to be recognized as mention of the these websites. But, tips as well as other interpretative papers to which recommendations could be supplied represent the views of these writers.

Amount 2B – Presentation and content associated with dossier

Notice to candidates, amount 2B including the most popular Technical Document (CTD) (might 2008).

Electronic Application Types

The usage of the electronic applications (eAF) is mandatory for several procedures from 1 January 2016. The eAFs can be used for several applications: authorisations, variants and renewals.

  • ESubmission: EU Electronic Application Forms (Module 1.2 application, renewal and variation kinds)
  • Concerns and Answers (2008 february)
  • Consumer guide for the application form that is electronic
    • An individual guide for the electronic form can be obtained on both CMDh internet site and eSubmission web site. To be noted that this guide is certainly not a NTA document anymore and links are available with this page for information. Regular change of the document that is commonfor centralised and decentralised applications) are going to be available entirely on these internet sites.
  • Electronic Popular Technical Document (eCTD)
    • EU Module 1 Specification
  • Change Control Process for European eCTD Requirements
    • Change Control Process for European eSubmission Criteria

      Content and requirements of applications

      From 1 2016 the paper (Word) application forms are not to be used for submissions anymore january. They’ve been obtainable in PDF just for information regarding the content and needs regarding the applications.

      Module 1.2 application (revision 14 – May 2019)


      • Form for variation to an advertising authorisation for medicinal services and products (individual and veterinary) to be used into the shared recognition together with centralised procedure (July 2018) – PDF variation


      • Form for renewal of an advertising authorisation (July 2018) – PDF variation

      Homeopathic Form

      Paper (Word) application continues to be available and may be properly used for submissions for homeopathic products that are medicinal.

      Module 1.2 Application that is homeopathic form version – December 2016)

      website that will write an essay for you